The Genetic Landscape of Human Glioblastoma and Matched Primary Cancer Stem Cells Reveals Intratumour Similarity and Intertumour Heterogeneity.
Journal
Stem cells international
ISSN: 1687-966X
Titre abrégé: Stem Cells Int
Pays: United States
ID NLM: 101535822
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
10
2018
accepted:
01
01
2019
entrez:
16
4
2019
pubmed:
16
4
2019
medline:
16
4
2019
Statut:
epublish
Résumé
Glioblastoma (GBM) is the most malignant human brain tumour, characterized by rapid progression, invasion, intense angiogenesis, high genomic instability, and resistance to therapies. Despite countless experimental researches for new therapeutic strategies and promising clinical trials, the prognosis remains extremely poor, with a mean survival of less than 14 months. GBM aggressive behaviour is due to a subpopulation of tumourigenic stem-like cells, GBM stem cells (GSCs), which hierarchically drive onset, proliferation, and tumour recurrence. The morbidity and mortality of this disease strongly encourage exploring genetic characteristics of GSCs. Here, using array-CGH platform, we investigated genetic and genomic aberration profiles of GBM parent tumour (
Identifiants
pubmed: 30984267
doi: 10.1155/2019/2617030
pmc: PMC6431486
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2617030Références
N Engl J Med. 2000 Nov 9;343(19):1350-4
pubmed: 11070098
J Neurooncol. 2000 Jun;48(2):89-94
pubmed: 11083071
Mol Cancer. 2004 Oct 06;3:25
pubmed: 15469606
Cancer Cell. 2006 May;9(5):391-403
pubmed: 16697959
Cancer Lett. 2007 Dec 8;258(1):55-62
pubmed: 17920192
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12
pubmed: 18077431
Clin Cancer Res. 2008 Jan 1;14(1):123-9
pubmed: 18172261
Cancer Cell. 2008 Apr;13(4):355-64
pubmed: 18394558
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
J Mol Diagn. 2010 Jul;12(4):425-32
pubmed: 20431034
Cancer. 2011 Jan 1;117(1):162-74
pubmed: 20806346
Clin Cancer Res. 2011 Jan 15;17(2):255-66
pubmed: 21097691
N Engl J Med. 2011 Feb 17;364(7):627-37
pubmed: 21175304
Exp Cell Res. 2011 Jul 1;317(11):1513-26
pubmed: 21514294
Genome Biol. 2011;12(4):R41
pubmed: 21527027
Mol Cytogenet. 2011 May 09;4:13
pubmed: 21554683
J Mol Diagn. 2011 Nov;13(6):634-47
pubmed: 21884817
Blood Cancer J. 2012 Nov 23;2:e96
pubmed: 23178508
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14
pubmed: 23412337
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6
pubmed: 23530248
Cancer Res. 2013 Jun 1;73(11):3193-9
pubmed: 23695554
Oncotarget. 2014 Mar 30;5(6):1515-25
pubmed: 24722048
World J Stem Cells. 2014 Apr 26;6(2):230-8
pubmed: 24772249
Glia. 2014 Dec;62(12):1968-81
pubmed: 25042636
Stem Cells Int. 2014;2014:838950
pubmed: 25580136
Stem Cells Int. 2015;2015:427518
pubmed: 26136784
J Neurooncol. 2015 Sep;124(3):447-53
pubmed: 26186902
Neuro Oncol. 2016 Mar;18(3):350-60
pubmed: 26245525
Handb Clin Neurol. 2016;134:97-120
pubmed: 26948350
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
J Neuropathol Exp Neurol. 2016 Jun 26;:
pubmed: 27346749
Onco Targets Ther. 2016 Jun 13;9:3485-92
pubmed: 27366085
Acta Neuropathol Commun. 2016 Aug 08;4(1):79
pubmed: 27503138
Oncologist. 2017 Apr;22(4):432-437
pubmed: 28275120
Neurotherapeutics. 2017 Apr;14(2):372-384
pubmed: 28374184
Int J Cancer. 2017 Nov 15;141(10):2002-2013
pubmed: 28710771
Clin Cancer Res. 2017 Nov 15;23(22):6846-6855
pubmed: 28855349
Oncotarget. 2017 Jul 8;8(34):57134-57148
pubmed: 28915660
PLoS One. 2017 Sep 21;12(9):e0185208
pubmed: 28934307
BMC Res Notes. 2017 Nov 6;10(1):560
pubmed: 29110683
Genes Dev. 2018 Apr 1;32(7-8):512-523
pubmed: 29632085
Nat Genet. 2018 May;50(5):708-717
pubmed: 29686388
Sci Rep. 2018 Jun 8;8(1):8748
pubmed: 29884885
Oncotarget. 2018 Jun 19;9(47):28421-28433
pubmed: 29983870
Neuro Oncol. 2019 Jan 1;21(1):95-105
pubmed: 30277538